Roche Diagnostics’ Locally Manufactured cobas t 711 Coagulation Solution Approved in China Roche Diagnostics announced the approval of its locally manufactured cobas t 711 Automated Coagu..

Junction, the infrastructure platform for diagnostic testing and health data workflows, today announced a collaboration with GRAIL to support scalable access to the Galleri® multi-cancer early detection test across digital health platforms and clinical organizations.

Illumina, Inc. (NASDAQ: ILMN) and Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration to advance precision oncology through innovative applications of next-generation sequencing (NGS) solutions across the healthcare ecosystem. Projects are expected to include promoting equitable access to cancer biomarker testing by bringing it closer to patients through new distributed test offerings; generating evidence to facilitate payer coverage; and developing new tests to address areas of unmet need.

Korea's diagnostics industry is buzzing as the Ministry of Food and Drug Safety (MFDS) moves to expand the range of conditions that can be tested with home diagnostic kits to include influenza and sexually transmitted diseases. Market growth expectations are rising as diagnostic kits previously restricted to professional use become available to general consumers. Companies are accelerating development of self-testing kits in response to the policy shift.

To ensure the quality and safety of medical services in primary healthcare institutions, China’s National Health Commission (NHC) and other relevant authorities issued a notice on 1 April 2026, outlining a three-year nationwide action.

PathAI, a leading provider of AI-powered pathology solutions, and MedStar Health, a leading health system headquartered in Columbia, Maryland, today announced a multi-year strategic collaboration to deploy PathAI’s AISight® Dx1 Digital Pathology Platform and various AI algorithm products across the multi-site network.

Waters Corporation (NYSE: WAT) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Onclarity HPV Self-Collection Kit and approved the BD Onclarity HPV Assay with extended genotyping for at-home use, marking a significant milestone in expanding access to cervical cancer screening, and removing barriers that currently prevent many individuals from receiving routine screening.

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, today announced the completion of its acquisition by funds managed by Blackstone and TPG in a transaction valued at up to $79 per share, establishing Hologic as a private company. The transaction includes significant minority investments from a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) and an affiliate of GIC. In connection with the completion of this transaction, Hologic today announced the appointment of José (Joe) E. Almeida as Chief Executive Officer, effective immediately.

3. Blood Typing Instruments and Its Technology Development Direction and Status of Market Development 3.1. Main Brands and Manufacturers of Domestic Automatic Blood Grouping Analyzers Micro..

Abbott (NYSE: ABT), the global healthcare company, and Flatiron Health, a leading healthtech company advancing point-of-care solutions in oncology, today announced the integration of Abbott’s comprehensive Precision Oncology portfolio into OncoEMR®, Flatiron’s cloud-based Electronic Medical Record (EMR) platform.

Co-Diagnostics, Inc. (NASDAQ: CODX) ("Co-Diagnostics," "Co-Dx," or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced its financial results for the full year ended December 31, 2025.

Merck, a leading science and technology company, today announced that it has successfully closed the acquisition of the chromatography business of JSR Life Sciences.

The World Health Organization (WHO) is issuing, for the first time, recommendations on new near-point-of-care (NPOC) molecular tests for the diagnosis of tuberculosis (TB); easy-to-collect tongue swab samples to simplify and expand access to testing; and a cost-saving sputum pooling strategy to increase testing efficiency for TB and rifampicin-resistant TB.

Lumos Diagnostics has today announced that U.S. FDA has granted 510(k) clearance with CLIA waiver for FebriDx®, enabling broader use across frontline healthcare settings and significantly expanding its commercial opportunity.

Original from: PR Newswire Roche announced today the U.S. Food and Drug Administration (FDA) 510(k) clearance of its newest analytical units – the cobas® c 703 and cobas® ISE neo. As part of the..

Original from: AmoyDx Amoy Diagnostics Co., Ltd., Medical ＆ Biological Laboratories Co., Ltd., a group company of Tokuyama Corporation, and Precision Medicine Asia Co., Ltd. today announced that MBL rec..

Original from: PR Newswire Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today the launch of the cobas® eplex respiratory pathogen panel 3 (RP3), a new diagnostic test designed to detect a broad spect..

We are excited to announce the 1st Global IVD Innovation Summit, taking place during CACLP 2026 in Xiamen! 🌍 📅 Date & Time: March 22, 2026 | 14:30–17:30 (GMT+8) Themed ..

Agilent Technologies, Inc. (NYSE: A) today reported revenue of $1.80 billion for the first quarter ended Jan. 31, 2026, representing growth of 7.0% reported and up 4.4% core(1) compared with the first quarter of 2025.

Diasorin (FTSE MIB: DIA) today announces the U.S. FDA approval of the LIAISON QuantiFERON-TB Gold Plus II assay as a next-generation automated Interferon Gamma Release Assay (IGRA) designed in partnership with QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) to enhance laboratory productivity, workflow efficiency and turnaround time for latent tuberculosis infection (LTBI) testing in the United States.